Anna Chérouvrier Hansson, Henrik Appelgren

Jul 18, 2017

Anna Chérouvrier Hansson is joining SenzaGen as the firm's chief commercial officer, and Henrik Appelgren will become its chief scientific officer. The firm said that the appointments are the final steps as it prepares to commercialize its GARD tests and to list on the Nasdaq First North. Hansson most recently was the director of marketing at Camurus. She begins her new job on Aug. 15. Appelgren has been with the Swedish Chemicals Agency for 15 years, where he was Sweden's national coordinator in the OECD Test Guideline Programme. He joins SenzaGen on Sept. 4. 

 

More Like This

Oct 12, 2018

David Stark

Parallax Diagnostics has appointed David Stark its president, the company's parent firm Parallax Health Sciences, said. Stark has more than 20 years of experience in healthcare R&D, clinical research, regulatory affairs, and marketing. He was director of development for clinical research organization Spaulding Clinical Research and director of business development, West Coast for MedSource. Before that, he was development director, West Coast for Veristat. 

Oct 12, 2018

Jane Schwebke

Talis Biomedical has appointed Jane Schwebke to its scientific advisory board. Both a professor of medicine in the infectious disease division at the University of Alabama at Birmingham and a consultant to the Jefferson County Department of Health STD clinic, Schwebke previously served as medical director of the Harborview STD Clinic in Seattle and as director for Chicago's STD/HIV Program.

Oct 11, 2018

Jörg Debatin

Jörg Debatin has been appointed chairman of the supervisory board of Hummingbird Diagnostics. Debatin previously served as VP and chief technology officer of GE Healthcare and CEO of Amedes. In addition, he has also served as the medical director and CEO of the University Hospital Hamburg-Eppendorf.

Oct 11, 2018

John Glasspool

VisionGate has appointed John Glasspool as Chief Operating and Strategy Officer and to the firm's board of directors. Glasspool is currently a member of the board of directors of Dalcor. In addition, he is an advisor to MIT Newdigs and leads the FoCUS project, looking at pricing and policy for durable oncology therapies. Glasspool's career includes executive and management responsibilities at pharmaceutical companies, including Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. Glasspool has also served on the board of directors and as president of Vaccines Europe at the Biotechnology Industry Organization.

Oct 10, 2018

Richard Yost

Owlstone Medical appointed Richard Yost to its scientific advisory board. He is a professor and head of analytical chemistry at the University of Florida and has particular expertise in tandem mass spectrometry. Yost is the co-inventor of the triple quadrupole mass spectrometer, Owlstone added. 

Oct 09, 2018

Michel Finance

Michel Finance is leaving his post as CEO of Theradiag, the company announced. No reason was given for his departure. Finance will stay on at Theradiag until Dec. 31. A search for his successor has begun. 

Oct 09, 2018

Susan Evans, Donna Edmonds

ImmunArray announced Susan Evans will become its new CEO, replacing Donna Edmonds, who will become the chair and CEO of ImmunArray's new spinoff called BrainBox Solutions based in Richmond, Virginia.

Evans began her career at Baxter Diagnostics and Dade Behring, where held various positions in R&D including senior vice president. She also held senior R&D postions in Caliper Life Sciences and Life Scan, and was vice president scientific affairs, and vice president/general manager of Beckman Coulter Genomics. 

Edmonds, meanwhile, will remain executive chair of ImmunArray. 

Oct 08, 2018

Stan Lapidus, Howard Heller, Margaret Higham

Atlas Genetics has changed its name to Binx Health and announced several additions to the company, including the appointment of Stan Lapidus as chairman of the board. Lapidus is the founder of Exact Sciences and Helicos BioSciences.

Also, Howard Heller was appointed Binx's chief medical officer while Margaret Higham was named its director of medical affairs. Heller directs infection control and prevention at the Massachusetts Institute of Technology and provides clinical care at Massachusetts General Hospital. Higham is an infectious disease expert and medical director of the Student Health Service at Tufts University.

Oct 04, 2018

David Grenache

The American Association of Clinical Chemistry announced that David Grenache has been elected to serve on the AACC board of directors as president-elect starting in January 2019. He will then serve as the association's president from August 2020 to July 2021, and past president from August 2021 to July 2022. Grenache is the chief scientific officer and medical director of the chemistry, immunology, and esoteric analytic chemistry labs at TriCore Reference Laboratories, and clinical professor of pathology at the University of New Mexico.

Oct 03, 2018

Tom Polen

Tom Polen, who currently serves as president of BD, has been promoted. He will now also serve as BD's Chief Operating Officer. Polen will be responsible for overseeing the firm's three operating segments, its new product development pipeline, and global operations including all manufacturing facilities and supply chain operations. The company has not had a COO since 2016, according to a statement.

Oct 03, 2018

Jürgen Schulze, Alain Baverel

Sysmex Europe announced that Jürgen Schulze, its chairman, long-time president, and CEO, retired at the end of September. He will continue to support Sysmex as a member and vice-chairman of the MedTech Europe Executive Board, the firm said.

Schulze passed the baton to Alain Baverel, who has been transitioning into his role as president and CEO of Sysmex EMEA since April 2018. His role became official Oct. 1.

Baverel joined Sysmex in 2007 as managing director of the newly established affiliate Sysmex France.

Oct 03, 2018

Hayden Jeffreys

Hayden Jeffreys has become group commercial director at Premaitha Health. He joined the company from Cambridge Epigenetix, where he was chief operating officer. Before that, he was interim CEO at ERBA Diagnostics. Jeffreys holds an MSc in management studies from the University of Oxford and a BSc in genetics from Cardiff University.

Oct 02, 2018

Lawrence Culp

Former Danaher President and CEO Lawrence Culp was named the Chairman and CEO of GE on Oct. 1, effective immediately. He replaces John Flannery in the two positions. Culp has been a member of GE's board since April and led Danaher between 2000 and 2014. 

Sep 27, 2018

Joan Martin

Accelerate Diagnostics has announced that Joan Martin has resigned from his position as executive vice president and head of Europe, the Middle East, and Africa, and will be leaving the company for personal reasons. Lawrence Mehren, Accelerate's president and CEO, will oversee operations of the region on an interim basis until the vacancy is filled.

Sep 27, 2018

Laurie Goodman

ClearLight Diagnostics has appointed Laurie Goodman as CEO. Goodman had been serving as interim CEO since 2018 and chief scientific officer since 2015. She will continue serving as board manager and provide executive leadership for the firm moving forward. Prior to ClearLight, Goodman was senior director of scientific and medical affairs for Biodesix, and held senior level positions at Affymetrix, Monogram Biosciences, and Lynx Therapeutics.